news
LMTK3 inhibitors could be an effective breast cancer therapy, say scientists
Researchers demonstrate that inhibiting the LMTK3 kinase is an effective anticancer strategy in murine models of breast cancer.
List view / Grid view
Thyroid cancer
news
Inhibiting sortilin could make pancreatic cancer therapies more effective
A study has shown that inhibiting sortilin, a neuroprotein known to have increased expression in cancers, reduces pancreatic cancer invasiveness in vitro.
article
Genomic medicine: cracking genomes to cure ‘incurable’ diseases
We are on the precipice of realising the true potential of genomics studies. Following completion of the Human Genome Project six years ago, huge strides have been made in understanding how the genome works, shedding light on disease pathogenesis and forging therapeutic efforts. In this article, Pushpanathan Muthuirulan explains how…
news
Nanoparticles used to deliver RNAi agents to thyroid cancer tumours
20 June 2016 | By Victoria White, Digital Content Producer
Researchers have developed an innovative nanoplatform that allows them to effectively deliver RNAi agents to the sites of cancer and suppress tumour growth...
news
Blueprint Medicines announces first preclinical data for BLU6864
23 June 2015 | By Victoria White
Blueprint Medicines has announced the first preclinical data for its drug candidate BLU6864, a RET-specific kinase inhibitor.
news
Rosetta Genomics and the Institute of Molecular Translational Medicine partner on development of Thyroid Cancer Diagnostic
22 October 2014 | By Rosetta Genomics Ltd
Rosetta Genomics Ltd. announces the initiation by the European Infrastructure for Translational Medicine, of a new public-private translational research project between Rosetta Genomics and the Institute of Molecular Translational Medicine (IMTM) at Palacky University, Olomouc, Czech Republic...